Amylyx Pharmaceuticals Investor Relations Material

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company's research and product development primarily target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to slow disease progression and improve patient outcomes. Amylyx leverages its scientific expertise in neurobiology to create therapies that address the underlying mechanisms of these diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.